Skip to main content

Clinical Studies

NCI-CONNECT has a number of studies that are open for adult patients with rare central nervous system (CNS) cancers. Check back as we plan to add more.

Online Study

Outcomes and Risk Project for Patients with Rare CNS Cancers

The project aims to improve our understanding of outcomes and risk factors related to the occurrence of rare CNS cancers. Research shows that certain risk factors may increase a person’s chances of developing cancer. Factors can include exposure to chemicals or other substances, and personal and family medical history. If you take part in this study, you will complete a web-based survey and submit a saliva sample that will be used for genetic testing.

Clinical Assessment

Evaluation of the Natural History and Specimen Banking for Patients with CNS Cancers

The study objective is to better understand brain and spinal cord tumors and uncover areas for further research. It also aims to connect patients with doctors who can help them manage their illness and give them new treatment options. 

Treatment Trials

Immune Checkpoint Inhibitor Nivolumab for Patients with Rare CNS Cancers

The clinical trial is investigating the immunotherapy drug nivolumab as an effective treatment for people with rare CNS tumors. 

Marizomib for Patients with Ependymoma

This clinical trial is investigating the drug marizomib as an effective treatment for people with recurrent ependymoma.

Nivolumab for Patients with IDH-Mutant Gliomas

This clinical trial is investigating the immunotherapy drug nivolumab as an effective treatment for people with recurrent IDH-mutant gliomas with and without hypermutator phenotype.

Sunitinib for Patients with Sarcomas of the CNS

This clinical trial is investigating the drug sunitinib as an effective treatment for people with either a gliosarcoma or primary brain sarcoma.

Carboplatin and Bevacizumab for Patients with Ependymoma

The clinical trial is investigating the combination of bevacizumab and carboplatin to help control recurrent ependymoma.